In today's ACT Brief, we examine the FDA's multi-domain transparency priorities, why radiopharmaceutical trials need redesigned infrastructure, and how AI can make enrollment more predictable.
News|Podcasts|April 27, 2026
ACT Brief: CRO Consolidation in Regulatory Services, Reimbursement in Development Planning, and Site Selection Misalignment
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine Veristat's acquisition of Certara's regulatory business, why reimbursement probability should inform development planning earlier, and how site selection misalignment drives downstream trial performance issues.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- Veristat
announced its intended acquisition of Certara's Regulatory and Medical Writing business, adding over 200 industry experts to its regulatory affairs and medical writing operations. The deal reflects broader consolidation in regulatory services, where sponsors increasingly seek partners managing the full arc of submission preparation without handoffs across multiple vendors, with closing expected in Q2 2026. - In part three of his
interview , Mark Freitas, managing director and life sciences practice lead at Alvarez & Marsal, made the case for integrating reimbursement probability into the standard PTRs framework earlier in development. Sponsors reaching approval without a viable value story face commercial barriers that could have been addressed upstream through earlier alignment between clinical efficacy and market access strategy. - In a new contributed
article , site selection misalignment drives predictable downstream consequences including delayed startup, lagging enrollment, and increased protocol deviations. High-performing sites treat feasibility strategically rather than administratively, and the industry should shift focus from volume to fit by improving transparency in selection criteria and engaging sites earlier in study planning.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine FDA input sought on early-phase ibogaine protocols, why mixed outsourcing models spread faster than oversight infrastructure, and a major partnership for a rare kidney disease treatment.
In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.
In today's ACT Brief, we examine how AI is surfacing endpoint options beyond traditional design thinking, why sponsor oversight of outsourced work often fails on inspection despite being robust in practice, and a new combination drug for advanced kidney cancer.
Trending on Applied Clinical Trials Online
1
FDA Releases Transparency Roadmap Outlining Disclosure Priorities Across Drug Development and Regulatory Review
2
FDA Seeks Public Input on Early-Phase Clinical Trial Design for Ibogaine
3
Beyond the Molecule: Why Radiopharmaceutical Trials Require a New Operating Model
4
Operation TrialBlazer Leveraging New and Anticipated US Policy Changes in Early Development
5